Ongoing investigation in our laboratory has motivated us to hypothesize that the molecular composition of plasma membrane microdomains associated with IGF-1R network receptors might dictate the tumorigenic activity of IRS-1/2 in breast cancer. This evidence concerns the gene IGF1R and breast carcinoma.